You are here:

Archived: Clostridium botulinum toxin type A neurotoxin (Botox®)


Following a full submission.

Not recommended for use within NHS Scotland

Clostridium botulinum toxin A (Botox) produces a localised reduction in muscle tone in patients with post-stroke hand and wrist spasticity and may improve disability. However, the place in therapy was not clearly defined nor was the economic case proven. The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Clostridium botulinum toxin type A neurotoxin (Botox®)
SMC Drug ID: 80/03
Manufacturer: Allergan Ltd
Indication: Focal spasticity of the wrist and hand associated with stroke in adults
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 November 2003

Current Advice

Resubmission 7 March 2011

Archived Advice

Resubmission 10 May 2004